Allergenis Hits the Milestone of Achieving 93% Accuracy in Their Proprietary Allergy Diagnosis Test

Washington, DC--(Newsfile Corp. - June 2, 2023) -  Allergenis, Inc. a pioneering provider of next-generation food allergy testing solutions, has achieved a significant milestone by reaching a remarkable 93% accuracy rate of its proprietary diagnostic test for peanut allergies. This breakthrough in accuracy empowers individuals and their families with concrete answers and a comprehensive understanding of their allergic status, ensuring a safer and more informed quality of life when living with a food allergy diagnosis.

The prevalence of food allergies remains a pressing issue, affecting 32 million Americans, including one in 13 children, and posing potential life-threatening reactions to this entire population. The burden of food allergies extends beyond physical health, significantly impacting the mental, emotional, and financial well-being of individuals, parents, and caregivers.

Existing food allergy testing methods have often fallen short of providing a complete understanding of an individual's allergy spectrum, leading to ambiguous and inaccurate results. Commonly used blood tests in the market for peanut allergies exhibit a staggering false-positive rate of up to 60%, while the gold standard tool, an oral food challenge (OFC), proves to be costly, time-consuming, and anxiety-inducing due to the potential risk of severe reactions. For these reasons OFC is often avoided.

In response to these challenges, Allergenis is transforming the landscape of food allergy diagnostics by offering patients more accurate and thorough testing and enhanced clarity concerning their food allergies. Leveraging cutting-edge systems biology and data analytics, Allergenis has developed a unique allergy diagnostic test that accurately and thoroughly determines an individual's allergic status and threshold.

"Our mission at Allergenis is to ensure that no one has to navigate life without definitive answers regarding the decisions that shape their well-being and the well-being of those around them. Our proprietary food allergy diagnosis test is designed to exceed the highest standards of safety, quality, and accuracy, providing families with clear and accurate information they can rely on," says Jim Garner, CEO of Allergenis.

The cornerstone of Allergenis' allergy diagnosis test is the proprietary bead-based epitope assay (BBEA), which demonstrates an exceptional 93% accuracy rate for peanut allergies. This advanced testing methodology, designed by experts and distilled to its simplest and purest purpose, addresses the critical question of whether an allergen can trigger a life-threatening reaction. With a focus on safety and accuracy, Allergenis aims to provide families with concrete answers and peace of mind.

When reporting an individual's allergic status, Allergenis goes beyond a simple binary result. The test incorporates a threshold risk stratification to determine the probability of safely consuming peanuts. By accurately diagnosing allergies and providing comprehensive information, Allergenis equips individuals with precise knowledge. This invaluable information empowers individuals to make informed decisions about their food choices and take appropriate precautions, enabling them to lead a safer and more fulfilling life.

"We understand that existing food allergy testing methods often fall short in providing a complete understanding of an individual's allergy spectrum. At Allergenis, we believe in empowering individuals and their families with accurate information to navigate their dietary choices confidently and avoid unnecessary risks", Jim Garner added.

The success of Allergenis' proprietary allergy diagnosis test has sparked optimism among the global medical community, recognizing the significance of achieving a 93% accuracy rate. Allergenis continues to collaborate with renowned research centers, academic institutions, and researchers across the United States, The UK, Europe, Australia, and beyond, further solidifying its position as a thought leader in the field.

As Allergenis reaches this important milestone, the company aims to accelerate its efforts to commercialize its revolutionary food allergy testing technology. To achieve this, Allergenis is actively seeking funding to support the development and deployment of its advanced testing solutions. The capital raised will enable Allergenis to establish a dedicated sales force, expand its commercial operations, and raise awareness among medical professionals, individuals, and their families.

Media Contact:
Name: Jim Garner
Email: jim.garner@allergenis.com

Source: The Newsdesk

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168547